ArticleJournal of clinical microbiology2002
Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran.International journal of peptide research and therapeutics · 2020Article
- Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.Journal of biosciences · 2017Review
- Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk.The Journal of general virology · 2015Article
- Expression of the novel hepatitis C virus core+1/ARF protein in the context of JFH1-based replicons.Journal of virology · 2015Article
- Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.World journal of gastroenterology · 2014Review
- Production and pathogenicity of hepatitis C virus core gene products.World journal of gastroenterology · 2014Review
- Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia.Arthritis research & therapy · 2014Article
- HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.PloS one · 2014Article
- Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.Journal of gastroenterology · 2012Article
- The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2011Article
- Functional characterization of core genes from patients with acute hepatitis C virus infection.The Journal of infectious diseases · 2010Article
- Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2010Article
- Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Screening of hepatocyte proteins binding to F protein of hepatitis C virus by yeast two-hybrid system.World journal of gastroenterology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The core protein of hepatitis C virus (HCV) has been implicated in hepatocarcinogenesis. In order to determine whether there is a correlation between mutations of the core protein and the development of hepatocellular carcinoma (HCC), the core protein-coding sequence of the viral genome of HCV subtype 1b (HCV-1b) obtained from patients with and without HCC was analyzed. We found that 12 (40.0%) of 30 HCV-1b isolates from patients with HCC but none of 29 isolates from patients without HCC had a point mutation(s) in an N-terminal region of 20 residues. Similarly, 10 (33.3%) of 30 isolates from patients with HCC had mutations in a limited region between residues 141 and 160, whereas only 2 (6.9%) of 29 isolates from patients without HCC did. The differences between the two groups were statistically significant. The mutations were found in isolates from both cancerous and adjacent noncancerous tissues of patients with HCC, suggesting that the mutations were present before the development of HCC. The other regions of the core protein of some isolates also had mutations, but no significant difference was observed between isolates from patients with HCC and those from patients without HCC. The F protein, a frameshift product that is still hypothetical for HCV-1b strains, showed more sequence diversity than the core protein among the isolates analyzed, but there were no significant differences in the mutation rates or positions between isolates from patients with HCC and isolates from patients without HCC, except for a short N-terminal sequence of approximately 11 residues that is shared with the core protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.